AAPL275.57-17.60 (-6.00%) ▼|ABBV242.35+7.46 (+3.17%) ▲|ABT93.42+2.93 (+3.23%) ▲|ACN127.86-1.29 (-1.00%) ▼|ADBE195.68-0.87 (-0.44%) ▼|AMAT648.89+59.93 (+10.17%) ▲|AMD524.13+5.08 (+0.98%) ▲|AMGN355.60+4.21 (+1.20%) ▲|AMT170.29-4.17 (-2.39%) ▼|AMZN228.39-5.99 (-2.55%) ▼|AVGO380.71-1.38 (-0.36%) ▼|AXP344.65+2.09 (+0.61%) ▲|BA219.33-0.92 (-0.42%) ▼|BAC58.15+0.42 (+0.72%) ▲|BKNG179.22-2.06 (-1.14%) ▼|BLK971.67-10.93 (-1.11%) ▼|BMY55.75+0.75 (+1.36%) ▲|BNY145.11+1.55 (+1.08%) ▲|BRK-B488.61-6.20 (-1.25%) ▼|C145.38+1.79 (+1.25%) ▲|CAT1,050.20+55.75 (+5.61%) ▲|CL91.22-0.67 (-0.72%) ▼|CMCSA22.86+0.22 (+0.97%) ▲|COF204.42+3.94 (+1.97%) ▲|COP106.45-0.48 (-0.44%) ▼|COST939.30-21.67 (-2.26%) ▼|CRM150.42-2.34 (-1.53%) ▼|CSCO118.54-1.20 (-1.00%) ▼|CVS104.23+2.36 (+2.32%) ▲|CVX171.35-0.10 (-0.06%) ▼|DE621.00+20.25 (+3.37%) ▲|DHR194.46+5.59 (+2.96%) ▲|DIS99.30-1.82 (-1.80%) ▼|DUK126.46-0.08 (-0.06%) ▼|EMR145.09+3.65 (+2.58%) ▲|FDX327.31+10.48 (+3.31%) ▲|GD344.85+0.53 (+0.15%) ▲|GE373.90+8.02 (+2.19%) ▲|GEV1,094.55+36.90 (+3.49%) ▲|GILD124.46-0.69 (-0.55%) ▼|GM79.14+0.19 (+0.24%) ▲|GOOG341.09-3.94 (-1.14%) ▼|GOOGL341.73-3.55 (-1.03%) ▼|GS1,079.75+2.84 (+0.26%) ▲|HD343.23+0.37 (+0.11%) ▲|HON232.19+4.77 (+2.10%) ▲|IBM259.44-3.52 (-1.34%) ▼|INTC130.41-1.51 (-1.14%) ▼|INTU256.00-6.33 (-2.41%) ▼|ISRG401.05-0.78 (-0.19%) ▼|JNJ243.97+2.97 (+1.23%) ▲|JPM336.72+3.27 (+0.98%) ▲|KO80.22-0.38 (-0.47%) ▼|LIN523.83+8.10 (+1.57%) ▲|LLY1,128.62+11.36 (+1.02%) ▲|LMT505.71+14.07 (+2.86%) ▲|LOW222.13+0.68 (+0.31%) ▲|LRCX392.88+18.06 (+4.82%) ▲|MA495.38+0.97 (+0.20%) ▲|MCD266.56-7.33 (-2.67%) ▼|MDLZ62.07+0.33 (+0.53%) ▲|MDT81.44+1.31 (+1.63%) ▲|META545.75-12.05 (-2.16%) ▼|MMM168.30+2.39 (+1.44%) ▲|MO72.86+0.79 (+1.10%) ▲|MRK123.53+2.93 (+2.43%) ▲|MS222.22+2.36 (+1.07%) ▲|MSFT351.60-13.85 (-3.79%) ▼|MU1,217.31+169.39 (+16.16%) ▲|NEE87.14-0.48 (-0.55%) ▼|NFLX71.76-0.09 (-0.12%) ▼|NKE41.12-0.71 (-1.69%) ▼|NOW90.42-3.38 (-3.60%) ▼|NVDA194.90-4.01 (-2.02%) ▼|ORCL152.24-5.29 (-3.36%) ▼|PEP140.24-2.04 (-1.43%) ▼|PFE24.00-0.04 (-0.17%) ▼|PG149.02-3.03 (-1.99%) ▼|PLTR107.43-6.08 (-5.36%) ▼|PM178.42+1.11 (+0.62%) ▲|QCOM213.88+16.56 (+8.39%) ▲|RTX186.15+1.09 (+0.59%) ▲|SBUX103.04-0.48 (-0.46%) ▼|SCHW90.05-1.34 (-1.47%) ▼|SO95.32-0.46 (-0.48%) ▼|SPG223.89+1.74 (+0.78%) ▲|T22.43+0.06 (+0.25%) ▲|TMO509.42+17.22 (+3.50%) ▲|TMUS182.23+1.44 (+0.80%) ▲|TSLA373.73-1.74 (-0.46%) ▼|TXN310.90+7.79 (+2.57%) ▲|UBER72.71-1.14 (-1.54%) ▼|UNH414.83+9.03 (+2.23%) ▲|UNP265.61+5.65 (+2.17%) ▲|UPS108.51+2.37 (+2.23%) ▲|USB60.99+0.88 (+1.46%) ▲|V335.21+2.98 (+0.90%) ▲|VZ45.97+0.29 (+0.62%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.45-3.56 (-2.99%) ▼|XOM137.02+0.12 (+0.09%) ▲|AAPL275.57-17.60 (-6.00%) ▼|ABBV242.35+7.46 (+3.17%) ▲|ABT93.42+2.93 (+3.23%) ▲|ACN127.86-1.29 (-1.00%) ▼|ADBE195.68-0.87 (-0.44%) ▼|AMAT648.89+59.93 (+10.17%) ▲|AMD524.13+5.08 (+0.98%) ▲|AMGN355.60+4.21 (+1.20%) ▲|AMT170.29-4.17 (-2.39%) ▼|AMZN228.39-5.99 (-2.55%) ▼|AVGO380.71-1.38 (-0.36%) ▼|AXP344.65+2.09 (+0.61%) ▲|BA219.33-0.92 (-0.42%) ▼|BAC58.15+0.42 (+0.72%) ▲|BKNG179.22-2.06 (-1.14%) ▼|BLK971.67-10.93 (-1.11%) ▼|BMY55.75+0.75 (+1.36%) ▲|BNY145.11+1.55 (+1.08%) ▲|BRK-B488.61-6.20 (-1.25%) ▼|C145.38+1.79 (+1.25%) ▲|CAT1,050.20+55.75 (+5.61%) ▲|CL91.22-0.67 (-0.72%) ▼|CMCSA22.86+0.22 (+0.97%) ▲|COF204.42+3.94 (+1.97%) ▲|COP106.45-0.48 (-0.44%) ▼|COST939.30-21.67 (-2.26%) ▼|CRM150.42-2.34 (-1.53%) ▼|CSCO118.54-1.20 (-1.00%) ▼|CVS104.23+2.36 (+2.32%) ▲|CVX171.35-0.10 (-0.06%) ▼|DE621.00+20.25 (+3.37%) ▲|DHR194.46+5.59 (+2.96%) ▲|DIS99.30-1.82 (-1.80%) ▼|DUK126.46-0.08 (-0.06%) ▼|EMR145.09+3.65 (+2.58%) ▲|FDX327.31+10.48 (+3.31%) ▲|GD344.85+0.53 (+0.15%) ▲|GE373.90+8.02 (+2.19%) ▲|GEV1,094.55+36.90 (+3.49%) ▲|GILD124.46-0.69 (-0.55%) ▼|GM79.14+0.19 (+0.24%) ▲|GOOG341.09-3.94 (-1.14%) ▼|GOOGL341.73-3.55 (-1.03%) ▼|GS1,079.75+2.84 (+0.26%) ▲|HD343.23+0.37 (+0.11%) ▲|HON232.19+4.77 (+2.10%) ▲|IBM259.44-3.52 (-1.34%) ▼|INTC130.41-1.51 (-1.14%) ▼|INTU256.00-6.33 (-2.41%) ▼|ISRG401.05-0.78 (-0.19%) ▼|JNJ243.97+2.97 (+1.23%) ▲|JPM336.72+3.27 (+0.98%) ▲|KO80.22-0.38 (-0.47%) ▼|LIN523.83+8.10 (+1.57%) ▲|LLY1,128.62+11.36 (+1.02%) ▲|LMT505.71+14.07 (+2.86%) ▲|LOW222.13+0.68 (+0.31%) ▲|LRCX392.88+18.06 (+4.82%) ▲|MA495.38+0.97 (+0.20%) ▲|MCD266.56-7.33 (-2.67%) ▼|MDLZ62.07+0.33 (+0.53%) ▲|MDT81.44+1.31 (+1.63%) ▲|META545.75-12.05 (-2.16%) ▼|MMM168.30+2.39 (+1.44%) ▲|MO72.86+0.79 (+1.10%) ▲|MRK123.53+2.93 (+2.43%) ▲|MS222.22+2.36 (+1.07%) ▲|MSFT351.60-13.85 (-3.79%) ▼|MU1,217.31+169.39 (+16.16%) ▲|NEE87.14-0.48 (-0.55%) ▼|NFLX71.76-0.09 (-0.12%) ▼|NKE41.12-0.71 (-1.69%) ▼|NOW90.42-3.38 (-3.60%) ▼|NVDA194.90-4.01 (-2.02%) ▼|ORCL152.24-5.29 (-3.36%) ▼|PEP140.24-2.04 (-1.43%) ▼|PFE24.00-0.04 (-0.17%) ▼|PG149.02-3.03 (-1.99%) ▼|PLTR107.43-6.08 (-5.36%) ▼|PM178.42+1.11 (+0.62%) ▲|QCOM213.88+16.56 (+8.39%) ▲|RTX186.15+1.09 (+0.59%) ▲|SBUX103.04-0.48 (-0.46%) ▼|SCHW90.05-1.34 (-1.47%) ▼|SO95.32-0.46 (-0.48%) ▼|SPG223.89+1.74 (+0.78%) ▲|T22.43+0.06 (+0.25%) ▲|TMO509.42+17.22 (+3.50%) ▲|TMUS182.23+1.44 (+0.80%) ▲|TSLA373.73-1.74 (-0.46%) ▼|TXN310.90+7.79 (+2.57%) ▲|UBER72.71-1.14 (-1.54%) ▼|UNH414.83+9.03 (+2.23%) ▲|UNP265.61+5.65 (+2.17%) ▲|UPS108.51+2.37 (+2.23%) ▲|USB60.99+0.88 (+1.46%) ▲|V335.21+2.98 (+0.90%) ▲|VZ45.97+0.29 (+0.62%) ▲|WFC84.74+0.44 (+0.52%) ▲|WMT115.45-3.56 (-2.99%) ▼|XOM137.02+0.12 (+0.09%) ▲|
26.5 C
New York
Thursday, June 25, 2026

Tag: agents

newssourceFORcompanyinformationcontent1marketreleases

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

Fujitsu launches solution to enhance customers’ global supply chain resilience

AI-driven rapid profit impact analysis supports optimal decision-making KAWASAKI, Japan, July 3, 2025 /PRNewswire/ -- Fujitsu Limited today announced the launch of a new solution...

Fujitsu launches solution to enhance customers’ global supply chain resilience

AI-driven rapid profit impact analysis supports optimal decision-making KAWASAKI, Japan, July 4, 2025 /PRNewswire/ -- Fujitsu Limited today announced the launch of a new solution...

Fujitsu launches solution to enhance customers’ global supply chain resilience

AI-driven rapid profit impact analysis supports optimal decision-making KAWASAKI, Japan, July 4, 2025 /PRNewswire/ -- Fujitsu Limited today announced the launch of a new solution...

Tencent Cloud Newsletter Featuring Gartner Research: Data+AI Enabled NextGen Data Intelligence Platform

HONG KONG, July 4, 2025 /PRNewswire/ -- On June 28, Tencent Cloud released a newsletter titled Data + AI: Build NextGen Data Intelligence Platform featuring...

Fujitsu launches solution to enhance customers’ global supply chain resilience

AI-driven rapid profit impact analysis supports optimal decision-making KAWASAKI, Japan, July 3, 2025 /PRNewswire/ -- Fujitsu Limited today announced the launch of a new solution...

Fujitsu launches solution to enhance customers’ global supply chain resilience

AI-driven rapid profit impact analysis supports optimal decision-making KAWASAKI, Japan, July 3, 2025 /CNW/ -- Fujitsu Limited today announced the launch of a new solution...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater ChinaBrii Biosciences retains ex-Greater China rights to address the global antimicrobial...

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management. 
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

High-Potency OTC NMN Supplement from Wonderfeel Launches Amid Surging Demand for Clean NAD+ Support Solutions

Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support. 
Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

Gluco6 Recognized for Strong Ingredient Transparency and OTC GLUT-4 Nutritional Support

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness 
Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAgents

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers